• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Pulmatrix

edit

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Milestones

edit

• 
  Pulmatrix added Eva Jack as CBO.
  Posted 12/15/10 at 6:50pm
• 
  Pulmatrix received $14M in Series B funding. (8/15/11)
  Posted 8/15/11 at 4:07am via businesswire.com
• 
  Pulmatrix received $5.7M in Grant funding. (12/14/10)
  Posted 12/15/10 at 6:44pm via dowjones.com
• 
  Pulmatrix received $3.5M in Series A funding. (3/11/09)
  Posted 11/11/09 at 5:38pm via masshightech.com
• 
  Pulmatrix received $30.2M in Series B funding. (11/2/09)
  Posted 11/11/09 at 5:38pm via xconomy.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/28/10

Sources

1. Mass High Tech (masshightech.com) [edit]
2. Xconomy Boston (xconomy.com) [edit]
3. Pulmatrix Secures $5.7M Darpa Grant, Hires Eva Jack As CBO (fis.dowjones.com) [edit]
4. Pulmatrix Secures a $14 million Financing to Advance Clinical Programs in COPD and Cystic Fibrosis (eon.businesswire.com) [edit]